Long-term follow-up of hepatitis B treatments
Part of Digestive system, Infections clinical trials.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old, and if you’re over 70 you should be in generally stable health
- You have had hepatitis B showing on blood tests for more than 6 months, or liver changes from hepatitis B seen on testing
- You are currently taking (or plan to start) one of these: entecavir, tenofovir disoproxil, tenofovir alafenamide, or another listed tenofovir option
- Or you are planning to take pegylated interferon (pegIFNα-2b), with or without prior hepatitis B treatment
- You agree to join the study and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a retreatment with pegylated interferon for people with chronic hepatitis B who have previously received interferon therapy and have seen their hepatitis B surface antigen (HBsAg) levels drop by at least half. The goal is to see if this retreatment can completely clear the virus from the blood.
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
This study follows patients who completed a previous trial of peginterferon alfa-2b and tenofovir for chronic hepatitis B. It checks long-term health and offers further treatment options based on your response to the earlier therapy.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.